Finance

Lists
Why is OCS down 4.04%?
Dive Deeper
OCS:NASDAQ
Oculis Holding AG
$8.31
-4.04%
(-0.35) 1D
Oct 9, 3:53:42 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for OCS...
Open
$8.60
High
$8.75
Low
$8.30
Mkt. cap
512.99M
Avg. vol.
246.79K
Volume
98.56K
52-wk high
$34.13
52-wk low
$8.30
EPS
-$1.68
Beta
0.26
Shares outstanding
61.59M
No. of employees
60
Open
$8.60
High
$8.75
Low
$8.30
Mkt. cap
512.99M
Avg. vol.
246.79K
Volume
98.56K
52-wk high
$34.13
52-wk low
$8.30
EPS
-$1.68
Beta
0.26
Shares outstanding
61.59M
No. of employees
60
News stories
From web sources and news partners
About Oculis Holding AG
CEO-
Employees60
Founded2017
HeadquartersZug, Zug, Switzerland
SectorPharmaceutical industry
Websiteoculis.com
Analyst ratings
Based on 7 analysts giving stock ratings to OCS in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for OCS in the last 3 months.
Highest
Current $8.31
$45.00 (+441.52%)
Average
$36.43 (+338.39%)
Lowest
$20.00 (+140.67%)
Analyst
Recommendation
Action
Price target
Projected
Date
Annabel Samimy
Stifel Nicolaus
Buy
Reiterated
$40.00
+381.3%
09/28/2026
Yi Chen
H.C. Wainwright
Buy
Reiterated
$39.00
+369.3%
09/18/2026
Tessa Romero
J.P. Morgan
Buy
Reiterated
$20.00
+140.7%
08/14/2026
Patrick Dolezal
LifeSci Capital
Buy
Maintained
$41.00
+393.4%
08/08/2026
Serge Belanger
Needham
Buy
Maintained
$38.00
+357.3%
08/07/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$45.00
+441.5%
08/06/2026
Jason Gerberry
Bank of America Securities
Buy
Reiterated
$32.00
+285.1%
08/07/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
$40.00
+381.3%
06/02/2026
Colleen M. Kusy
Robert W. Baird
Buy
Maintained
$38.00
+357.3%
06/01/2026
Daniil Gataulin
Chardan Capital
Buy
Reiterated
$53.00
+537.8%
05/12/2026
Previous reportsAll values in CHF
Loading Previous Earnings...
Revenue
Net income
All values in CHF
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
243.00K
411.00K
209.00K
310.00K
Cost of goods sold
14.12M
13.29M
14.05M
15.28M
Cost of revenue
14.12M
13.29M
14.05M
15.28M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.42M
7.76M
7.89M
8.60M
Operating expense
6.42M
7.76M
7.89M
8.60M
Total operating expenses
20.54M
21.04M
21.94M
23.88M
Operating income
-20.30M
-20.63M
-21.73M
-23.57M
Other non operating income
3.09M
-3.24M
-7.98M
12.10M
EBT including unusual items
-16.84M
-23.70M
-28.95M
-9.96M
EBT excluding unusual items
-16.84M
-23.70M
-28.95M
-9.96M
Income tax expense
13.00K
-182.00K
-98.00K
6.00K
Effective tax rate
-0.08%
0.77%
0.34%
-0.06%
Other operating expenses
-
-
-
-
Net income
-16.86M
-23.51M
-28.85M
-9.97M
Net profit margin
-6,936.21%
-5,721.17%
-13,804.78%
-3,216.13%
Earnings per share
-0.32
-0.42
-0.49
-0.16
Interest and investment income
438.00K
319.00K
367.00K
592.00K
Interest expense
-162.00K
-241.00K
-173.00K
-309.00K
Net interest expenses
276.00K
78.00K
194.00K
283.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-20.14M
-20.60M
-21.57M
-23.39M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps